Serrapeptase: Evidence Review for Anti-Inflammatory & Mucolytic Use

Serrapeptase (serratiopeptidase) is a proteolytic enzyme from Serratia marcescens (originally silkworm gut symbiont). Used in Japan (Danzan®) and Europe for decades as an anti-inflammatory, anti-edema, and mucolytic agent.

Proposed Mechanisms

• Proteolysis: Degrades fibrin, bradykinin, inflammatory mediators → ↓ vascular permeability, ↓ edema.
• Mucolytic: Reduces mucus viscosity by cleaving disulfide bonds in mucoproteins.
• Modulates prostaglandins/cytokines: ↓ PGE₂, IL-1β, TNF-α in some models.
• Biofilm disruption: May enhance antibiotic penetration.

Clinical Evidence (Human Studies)

• Post-surgical swelling/pain: Several RCTs (dental, ENT, orthopedic) show ↓ edema, pain, trismus vs. placebo/NSAIDs. Quality moderate.
• Sinusitis / bronchitis: Improved secretion clearance, symptom scores in some trials. Often combined with antibiotics.
• Chronic airway diseases (COPD, bronchiectasis): Limited data; mucolytic effect plausible.
• Fibrotic conditions (carpal tunnel, Dupuytren's): Case reports/small studies; not established.
• Arthritis: Insufficient evidence for routine use.

Safety & Pharmacokinetics

• Enteric-coated tablets (protect from gastric acid degradation).
• Absorbed intact across intestinal mucosa → systemic distribution.
• Generally well-tolerated. GI upset, nausea, rare allergic reactions.
• Drug interactions: Theoretical ↑ bleeding risk with anticoagulants/antiplatelets (fibrinolytic effect). Monitor.

Regulatory Status

• USA: Dietary supplement (DSHEA). Not FDA-approved as drug.
• Japan/Europe: Approved pharmaceutical (prescription/OTC).

Bottom Line

Promising for post-operative edema, sinusitis, and mucus clearance. Evidence for chronic pain, arthritis, fibrosis is weak. Not a substitute for disease-modifying therapy. Consult clinician before use, especially if on anticoagulants or facing surgery.